drugset / Trial / NCT03944499
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
NaSingle-groupOpen-labelTreatment
Summary
The study comprises two phases: Phase 1a and Phase 1b. The purpose of the study is to observe the safety， tolerability and efficacy of FS-1502.
Timeline
- Start
- 2019-10-11
- Primary completion
- 2024-05-20
- Completion
- 2024-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRASTUZUMAB MAFODOTIN | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | TRASTUZUMAB MAFODOTIN | Monoclonal antibody | 0.2 mg/kg | Intravenous |
| Subject | TRASTUZUMAB MAFODOTIN | Monoclonal antibody | 0.4 mg/kg | Intravenous |
| Subject | TRASTUZUMAB MAFODOTIN | Monoclonal antibody | 0.6 mg/kg | Intravenous |
| Subject | TRASTUZUMAB MAFODOTIN | Monoclonal antibody | 0.8 mg/kg | Intravenous |
| Subject | TRASTUZUMAB MAFODOTIN | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | TRASTUZUMAB MAFODOTIN | Monoclonal antibody | 1.3 mg/kg | Intravenous |